Bibliography
- Choi ES, Hokom MM, Chen JL, et al. The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis. Br J Haematol 1996;95:227-33
- Gordon MS, Mccaskill-stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996;87:3615-24
- Tepler I, Elias L, Smith JW 2nd, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996;87:3607-14
- Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002;100:3457-69
- Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001;98:3241-8
- Kuter DJ. New thrombopoietic growth factors. Blood 2007;109:4607-16
- Evangelista ML, Amadori S, Stasi R. Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use. Current drug discovery technologies 2007;4:162-73
- Vigon I, Mornon JP, Cocault L, et al. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 1992;89:5640-4
- Skoda RC, Seldin DC, Chiang MK, et al. Murine c-mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal. EMBO J 1993;12:2645-53
- Le Coniat M, Souri M, Vigon I, et al. The human homolog of the myeloproliferative virus maps to chromosome band 1p34. Hum genet 1989;83:194-6
- Alexander WS, Dunn AR. Structure and transcription of the genomic locus encoding murine c-Mpl, a receptor for thrombopoietin. Oncogene 1995;10:795-803
- Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990;87:6934-8
- Mignotte V, Vigon I, Boucher de Crevecoeur E, et al. Structure and transcription of the human c-mpl gene (MPL). Genomics 1994;20:5-12
- Deveaux S, Filipe A, Lemarchandel V, et al. Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes. Blood 1996;87:4678-85
- Kiladjian JJ, Elkassar N, Hetet G, et al. Study of the thrombopoitin receptor in essential thrombocythemia. Leukemia 1997;11:1821-6
- Li J, Sabath DF, Kuter DJ. Cloning and functional characterization of a novel c-mpl variant expressed in human CD34 cells and platelets. Cytokine 2000;12:835-44
- Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995;85:391-401
- Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol 1999;106:345-56
- Wolber EM, Jelkmann W. Thrombopoietin: the novel hepatic hormone. News Physiol Sci 2002;17:6-10
- Alexander WS, Metcalf D, Dunn AR. Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. EMBO J 1995;14:5569-78
- Feese MD, Tamada T, Kato Y, et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci USA 2004;101:1816-21
- Sabath DF, Kaushansky K, Broudy VC. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood 1999;94:365-7
- Erickson-Miller CL, Delorme E, Iskander M, et al. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist [abstract 2909]. Blood 2004;104
- Kim MJ, Park SH, Opella SJ, et al. NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains. J Biol Chem 2007;282:14253-61
- Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005;115:3339-47
- Livnah O, Stura EA, Middleton SA, et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science (NY) 1999;283:987-90
- Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science (NY) 1999;283:990-3
- Tortolani PJ, Johnston JA, Bacon CM, et al. Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2. Blood 1995;85:3444-51
- Kaushansky K. Thrombopoietin and the hematopoietic stem cell. Ann NY Acad Sci 2005;1044:139-41
- Ezumi Y, Takayama H, Okuma M. Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett 1995;374:48-52
- Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008;68:901-12
- Erickson-Miller CL, Delorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005;33:85-93
- Duffy KJ, Price AT, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics. J Med Chem 2002;45:3576-8
- Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood 1999;94:1273-82
- Erickson-Miller C, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietin Receptor Agonist. Stem Cells; In press
- Us Food and Drug Administration. 2008 Center for Drug Evaluation and Research (CDER) Meeting Documents. Oncologic Drugs Advisory Committee May 30, 2008. Available from: http://wwwfdagov/ohrms/dockets/AC/cder08html [Last accessed 15 October 2008]
- Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109:4739-41
- Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237-47
- Bussel J, Provan A, Shamsi T, et al. Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: a phase III study [abstract 0390]. Haematologica 2007;92(Suppl 1)
- Bussel JB, Cheng G, Saleh M, et al. Long-term safety and efficacy of oral eltrombopag for the treatment of idiopathic thrombocytopenic purpura (ITP) [abstract 0949]. Haematologica 2008;93
- Psaila B, Bussel JB, Vasey S, et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic ITP [abstract 0294]. Haematologica 2008;93
- Mchutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-36
- Gernsheimer T. Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur J Haematol Suppl 2008;3-8
- George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006;4:1664-72
- Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14
- Sulkowski MS. Management of the hematologic complications of hepatitis C therapy. Clin Liver Dis 2005;9:601-16
- Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000;95:2936-9
- Roberts SA. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics. Xenobiotica 2001;31:557-89
- Schwardt O, Kolb H, Ernst B. Drug discovery today. Curr Top Med Chem 2003;3:1-9
- Muegge I. Selection criteria for drug-like compounds. Med Res Rev 2003;23:302-21
- Rees DC, Congreve M, Murray CW, Carr R. Fragment-based lead discovery. Nat Rev 2004;3:660-72
- Scheuermann J, Dumelin CE, Melkko S, Neri D. DNA-encoded chemical libraries. J Biotechnol 2006;126:568-81
- Kaushansky K. Hematopoietic growth factor mimetics. Ann NY Acad Sci 2001;938:131-8
- Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997;276:1696-9
- de Serres M, Ellis B, Dillberger JE, et al. Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man. Stem Cells 1999;17:203-9
- Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004;76:628-38
- Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7:715-25